Letter to the Editor: Lapatinib Confounds Post-Hoc Weight Loss Analysis in the ALTTO Trial

Affiliations

¹ aDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; and.
² bDepartment of Adult Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

Comment

Neil M Iyengar et al. J Natl Compr Canc Netw. 2022 Jan.

. 2022 Jan;20(1):xliv-xlv.

doi: 10.6004/jnccn.2021.7082.

¹ aDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; and.
² bDepartment of Adult Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

No abstract available

Comment in

Authors' Reply To the Letters to the Editor by Puklin et al and by Iyengar and Ligibel.
Martel S, Lambertini M, de Azambuja E. Martel S, et al. J Natl Compr Canc Netw. 2022 Jan;20(1):xlv-xlvi. doi: 10.6004/jnccn.2021.7110. J Natl Compr Canc Netw. 2022. PMID: 34991073 No abstract available.

Body Mass Index and Weight Change in Patients With HER2-Positive Early Breast Cancer: Exploratory Analysis of the ALTTO BIG 2-06 Trial.
Martel S, Lambertini M, Agbor-Tarh D, Ponde NF, Gombos A, Paterson V, Hilbers F, Korde L, Manukyants A, Dueck A, Maurer C, Piccart M, Moreno-Aspitia A, Desmedt C, Di Cosimo S, de Azambuja E. Martel S, et al. J Natl Compr Canc Netw. 2021 Jan 5;19(2):181-189. doi: 10.6004/jnccn.2020.7606. J Natl Compr Canc Netw. 2021. PMID: 33401235 Clinical Trial.